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Abstract
Recognition of viral RNA structures by the intracytosolic RNA helicase RIG-I triggers induction of innate immunity. Efficient
induction requires RIG-I ubiquitination by the E3 ligase TRIM25, its interaction with the mitochondria-bound MAVS protein,
recruitment of TRAF3, IRF3- and NF-kB-kinases and transcription of Interferon (IFN). In addition, IRF3 alone induces some of
the Interferon-Stimulated Genes (ISGs), referred to as early ISGs. Infection of hepatocytes with Hepatitis C virus (HCV) results
in poor production of IFN despite recognition of the viral RNA by RIG-I but can lead to induction of early ISGs. HCV was
shown to inhibit IFN production by cleaving MAVS through its NS3/4A protease and by controlling cellular translation
through activation of PKR, an eIF2a-kinase containing dsRNA-binding domains (DRBD). Here, we have identified a third
mode of control of IFN induction by HCV. Using HCVcc and the Huh7.25.CD81 cells, we found that HCV controls RIG-I
ubiquitination through the di-ubiquitine-like protein ISG15, one of the early ISGs. A transcriptome analysis performed on
Huh7.25.CD81 cells silenced or not for PKR and infected with JFH1 revealed that HCV infection leads to induction of 49 PKR-
dependent genes, including ISG15 and several early ISGs. Silencing experiments revealed that this novel PKR-dependent
pathway involves MAVS, TRAF3 and IRF3 but not RIG-I, and that it does not induce IFN. Use of PKR inhibitors showed that
this pathway requires the DRBD but not the kinase activity of PKR. We then demonstrated that PKR interacts with HCV RNA
and MAVS prior to RIG-I. In conclusion, HCV recruits PKR early in infection as a sensor to trigger induction of several IRF3-
dependent genes. Among those, ISG15 acts to negatively control the RIG-I/MAVS pathway, at the level of RIG-I
ubiquitination.These data give novel insights in the machinery involved in the early events of innate immune response.
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Introduction
IFN induction in response to several RNA viruses involves the
intracytosolic pathogen recognition receptor (PRR) CARD-
containing DexD/H RNA helicase RIG-I. Following its binding
to viral RNA, RIG-I undergoes a change in its conformation
through Lys63-type ubiquitination by the E3 ligase TRIM25. This
allows its N-terminal CARD domain to interact with the CARD
domain of the mitochondria-bound adapter MAVS [1,2]. MAVS
then interacts with TRAF3 to further recruit downstream IRF3
and NF-kB-activating kinases, that stimulate the IFNb promoter
in a cooperative manner. In addition, IRF3 stimulates directly the
promoters of some interferon-induced genes (early ISGs) while
NF-kB stimulates that of inflammatory cytokines [3].
The RNA of Hepatitis C virus (HCV) has an intrinsic ability to
trigger IFNb induction through RIG-I [4,5,6]. Yet HCV is a poor
IFN inducer. One reason for this comes from the ability of its NS3
protease to cleave MAVS [7]. Another relates to the ability of
HCV to trigger activation of the dsRNA-dependent eIF2a kinase
PKR [8,9] which leads to inhibition of IFN expression through
general control of translation while the viral genome can be
translated from its eIF2a-insensitive IRES structure [8].
HCV infection can trigger important intrahepatic synthesis of
several IFN-induced genes (ISGs) in patients [10,11] and in animal
models of infection in chimpanzees [12]. Expression of ISGs can
be explained at least in part by the ability of HCV to activate the
IFN-producing pDCs in the liver through cell-to-cell contact with
HCV-infected cells [13]. Intriguingly, despite the recognized
antiviral activity of a number of these ISGs, their high expression
paradoxically represents a negative predictive marker for the
response of these patients to standard combination IFN/ribavirin
therapy [14,15,16]. The ubiquitine-like protein ISG15 is among
the ISGs which are the most highly induced by HCV [16] and
was recently shown to act as a pro-HCV agent [17]. Interestingly,
ISG15 was also shown to control RIG-I activity through
ISGylation [18].
Here, we show that HCV controls IFN induction at the level of
RIG-I ubiquitination through the ubiquitine-like protein ISG15,
one of the early ISGs. Use of small interfering RNA (siRNA)
targeting to compare the effect of ISG15 to that of PKR on IFN
induction and HCV replication led to the unexpected finding that
HCV infection triggers induction of ISG15 and other ISGs by using
PKR as an adapter through its N terminal dsRNA binding domain.
This recruits a signaling pathway which involves MAVS,TRAF3
PLoS Pathogens | www.plospathogens.org 1 October 2011 | Volume 7 | Issue 10 | e1002289and IRF3 but not RIG-I. Altogether, our results present a novel
mechanism by which HCV uses PKR and ISG15 to attenuate the
innate immune response.
Results
HCV infection negatively controls RIG-I ubiquitination
We recently reported that the HCV permissive Huh7.25.CD81
cells [19] that we used to identify the pro-HCV action of PKR, did
not induce IFN in response to HCV infection, unless after ectopic
expression of TRIM25 [8]. We started this study by investigating
at which level this defect could occur. A P358L substitution in the
endogenous TRIM25 of these cells, revealed by sequence analysis,
proved to have no incidence of the ability of TRIM25 to
participate in the IFN induction process. Indeed, ectopic
expression of a TRIM25 P358L construct was as efficient as a
TRIM25wt construct to increase IFN induction in the
Huh7.25.CD81 cells, after infection with Sendai virus (SeV)
(Figure 1A). Like some other members of the TRIM family,
TRIM25 is localized in both the cytosol and nucleus and is
induced upon IFN treatment [20]. No specific difference between
the cellular localization of TRIM25 was observed in the
Huh7.25.CD81 cells when compared to Huh7 cells or Huh7.5
cells, which rules out a role for a cellular mislocalization in its
inability to participate in IFN induction (Figure 1B). TRIM25
was also efficiently induced by IFN (Figure 1B and Figure S1).
We assayed whether increasing TRIM25 upon IFN treatment
could mimic the effect of its ectopic expression and restore IFN
induction in response to HCV infection. However, this resulted
only in a poor stimulation of an IFNb promoter (3 to 5-fold), in
contrast to its effect upon SeV infection (230-fold) (Figure 1C).
Similarly, HCV infection at higher m.o.i, as an attempt to favour
recognition of RIG-I by the viral RNA, only modestly increased
IFN induction (Figure 1D). TRIM25 plays an essential role in
IFN induction through RIG-I ubiquitination [1]. We then
analysed whether this step was affected by HCV infection in the
Huh7.25.CD81 cells. The results showed that, in contrast to SeV
infection used as control, HCV infection could not trigger RIG-I
ubiquitination, unless the cells are supplied with ectopic TRIM25
(Figure 1E). Thus, HCV infection appears to mediate a control
on IFN induction through regulation of RIG-I ubiquitination.
HCV controls RIG-I ubiquitination through ISG15
Inhibition of the function of TRIM25 or RIG-I ubiquitination
has been suggested to occur via the small ubiquitin-like protein
ISG15 and the process of ISGylation [18,21]. We then analysed
whether ISG15 was involved in the control of RIG-I ubiquitina-
tion upon HCV infection. For this, we chose a transient
transfection approach using siRNAs targeting ISG15 in the
Huh7.25.CD81 cells. Indeed, this resulted in a strong ubiquitina-
tion of RIG-I at 9 hrs and 12 hrs post-HCV infection, which was
equivalent to that observed in cells supplied with ectopic TRIM25
(Figure 2A). A similar result was obtained after JFH1 infection in
the Huh7 cells, used as another HCV-permissive cell line (Figure
S2). Thus, ISG15 can control RIG-I ubiquitination in different
cells infected by HCV. We next investigated whether ISGylation
was involved in this process. Absence of detection of RIG-I
ubiquitination after HCV infection of the Huh7.25.CD81 cells
precludes direct analysis of the effect of ISG15 on RIG-I. We used
an IFNb-luc reporter assay instead, as it proved to be sensitive
enough to detect some IFN induction in response to JFH1
infection in those cells (see Figure 1D). We found that IFN
induction increased when cells were transfected with siRNAs
targeting ISG15 while it decreased in cells overexpressing IGS15
(Figure 2B). Expression of ISG15 in the presence of the E1, E2
and E3 ligases involved in ISGylation (respectively Ube1L, UbcH8
and HERC5) [22] further inhibits IFNb induction (Figure 2B).
Similar results were observed upon infection with Sendai virus
(Figure S3). The ISGylation process is strictly dependent on the
presence of the E1 ligase Ube1L [23]. Indeed, enhanced IFN
promoter activity has been observed in Ube1L2/2 cells in
response to NDV [18]. In accord with this, depletion of
endogenous Ube1L from the Huh7.25.CD81 cells (Figure S4),
as such or after ectopic expression of ISG15, UbcH8 and HERC5,
resulted in an increase in IFNb induction after infection with HCV
(Figure 2B). We then analysed the effect of siISG15 on IFNb
induction after infecting the cells with HCV up to 72 hours, in
order to pass through the 24 hr time-point where the signaling
pathway leading to the transcription of this gene is expected to
stop because of the NS3/4A-mediated cleavage of MAVS [8]. The
results show that, whereas IFNb transcription was indeed strongly
inhibited after 24 hr in the control cells, it still occurred
significantly in the cells expressing siRNA ISG15 (Figure 2C).
Previous data have shown a positive role for ISG15 on HCV
production [24,25]. In accord with this, silencing of ISG15
resulted in clear inhibition of HCV RNA expression with however
no significant consequence on the ability of the virions produced to
re-infect fresh cells (Figure 2D). Analysis of expression of MAVS
and NS3, as well as the expression of the core protein as another
example of viral protein, then showed that the depletion of ISG15
both decreased and delayed the expression of the viral proteins as
compared to the siRNA control cells and that this was correlated
by a delay in the NS3/4A-mediated cleavage of MAVS
(Figure 2E). These results show that ISG15 controls the process
of IFN induction during HCV infection by interfering with RIG-I
ubiquitination through an ISGylation process and by boosting
efficient accumulation of NS3, among other viral proteins, thus
favouring its negative control on IFN induction by cleavage of
MAVS.
ISG15 strengthens the pro-HCV activity of PKR
ISG15 ([24,25] and this study) and PKR [8,9] emerge as two
ISGs with pro-HCV activities, instead of playing an antiviral
role. We then assayed the effect of a combined depletion of PKR
and ISG15 on HCV replication and IFN expression in the
Huh7.25.CD81 cells. As shown in Figure 2 D and B, siRNAs
targeting ISG15 were sufficient both to inhibit HCV replication
(Figure 3A) and to increase IFNb expression, either measured by
RTqPCR (Figure 3B) or by using an IFNb-luciferase reporter
Author Summary
Hepatitis C Virus (HCV) is a poor interferon (IFN) inducer,
despite recognition of its RNA by the cytosolic RNA
helicase RIG-I. This is due in part through cleavage of
MAVS, a downstream adapter of RIG-I, by the HCV NS3/4A
protease and through activation of the eIF2a-kinase PKR to
control IFN translation. Here, we show that HCV also
inhibits RIG-I activation through the ubiquitin-like protein
ISG15 and that HCV triggers rapid induction of 49 genes,
including ISG15, through a novel signaling pathway that
precedes RIG-I and involves PKR as an adapter to recruit
MAVS. Hence, we propose to divide the acute response to
HCV infection into one early (PKR) and one late (RIG-I)
phase, with the former controlling the latter. Furthermore,
these data emphazise the need to check compounds
designed as immune adjuvants for activation of the early
acute phase before using them to sustain innate immunity.
HCV Controls IFN Induction through PKR and ISG15
PLoS Pathogens | www.plospathogens.org 2 October 2011 | Volume 7 | Issue 10 | e1002289Figure 1. HCV infection negatively controls RIG-I ubiquitination. (A) Huh7.25.CD81 cells were transfected for 24 hrs with 150 ng of the
pGL2-IFNb-FLUC; 40 ng of the pRL-TK-RLUC reporter plasmids alone or in presence of 150 ng of a plasmid expressing HA-TRIM25, either as such
(TRIM25wt) or containing the P358L substitution (a SNP rs75467764 with no reported pathology). Cells were infected or not with SeV (40 HAU/ml) for
24 hrs. IFN expression was expressed as fold induction of luciferase activity. Error bars represent the mean 6 S.D. for triplicates. (B) Huh7, Huh7.5 and
Huh7.25.CD81 cells were either untreated or treated with 500 U/ml IFNa for 24 hrs. TRIM25 was detected by immunoblot after preparation of nuclear
and cytosolic fractions from 25 mg of cell extracts. Detection of Actin, RIG-I and phosphorylated Histone 3 (HH3-P) served as controls. (C–D)
Huh7.25.CD81 cells were transfected with the reporter plasmids as in A, a few hours before being treated with 500 U/ml IFNa for 24 hrs (C) or left
untreated (Co rD ). They were then infected with Sendai virus (40 HAU/ml) or with JFH1 at an m.o.i of 0.2 (C) or increasing from 0.2 to 10 (D). At the
times indicated, IFN expression was expressed as fold induction of luciferase activity. Error bars represent the mean 6 S.D. for triplicates. Induction of
HCV Controls IFN Induction through PKR and ISG15
PLoS Pathogens | www.plospathogens.org 3 October 2011 | Volume 7 | Issue 10 | e1002289assay (Figure 3C). Very limited additional effect was observed in
the concomitant presence of siRNAs targeting PKR. (Figure 3B).
Interestingly, we noticed that expression of luciferase from the
IFNb promoter increased throughout the first 18 hours of HCV
infection in the siISG15 cells (Figure 3C). This was intriguing as it
should have been inhibited after 12 hours of HCV infection
through the eIF2a kinase activity of PKR and its control on
translation [8]. We therefore analysed whether the state of PKR
activation (phosphorylation) was dependent on the expression of
ISG15. For this, the Huh7.25.CD81 cells were transfected either
with siRNAs targeting ISG15 or with a plasmid expressing an HA-
ISG15 construct and PKR phosphorylation was analysed as
described previously [8]. The results showed that depletion of
ISG15 inhibits PKR activation in the HCV-infected cells, while its
overexpression stimulates it (Figure 3D and Figure S5).
Therefore these data reveal that, in addition to negatively
controlling RIG-I ubiquitination, ISG15 can also positively
control PKR activity. The conjugation of both effects results in
an efficient control of IFN induction during HCV infection.
HCV triggers a PKR-dependent pathway early in infection
to induce ISG15 and other genes
The Huh7.25.CD81 cells express ISG15 at significant basal
levels. This situation was not surprising as various cellular systems
can also express some of the ISGs at basal level. Expression of
ISG15 was approximately 2- and 5-fold higher in the
Huh7.25.CD81 cells than in the Huh7.5 or Huh7 cells (data not
shown). Intriguingly however, we noticed that ISG15 expression
was increased in response to HCV infection (see Figure 2E). To
investigate this further, we simply re-used the RNAs prepared for
the experiment shown in Figure 3B and performed a quantitative
kinetics analysis. The results confirmed that HCV can trigger
induction of ISG15 (Figure 4A). Unexpectedly, analysis of the
RNA extracted from the cells treated with siRNAs targeting PKR,
revealed that ISG15 RNA expression was strongly repressed when
PKR was silenced (Figure 4A). This surprising result was
confirmed by analysing induction of ISG56, another early ISG
[26], both at the level of its endogenous RNA (Figure 4B)o rb y
using an ISG56-luciferase vector (Figure 4C). In the latter case, a
strong increase of the reporter expression in the cells treated with
siRNAs targeting ISG15, was similar to the situation observed for
IFNb RNA (Figure 2B and 2C). This can be related to
activation of the RIG-I pathway, which can function when ISG15
is absent. These data suggest that HCV may use PKR to activate
gene transcription. Importantly, this phenomenon was specific to
HCV as infection with Sendai virus resulted in a similar induction
of ISG15 and ISG56, regardless of PKR (Figure 4D and Figure
S6). We then examined whether overexpression of PKR could
boost induction of ISG15 during HCV infection and how this
would affect HCV replication and IFN induction, in relation to the
pro-HCV action of ISG15. Huh7.25.CD81 cells were transfected
with a plasmid expressing PKR alone or in presence of siRNAs
targeting ISG15, before being infected with HCV over 48 hours.
Overexpression of PKR increased the ability of HCV to induce
ISG15 and concomitantly, led to an increase in HCV RNA
expression. The latter increase was abolished when ISG15 was
silenced, thus showing that the PKR-dependent increase in HCV
expression is mediated by ISG15 (Figure 4E). However, while the
cells silenced for ISG15 are able to induce IFN in response to
HCV infection, as shown in Figure 3B, they are unable to do so
when PKR is overexpressed. This suggests that PKR may also
interfere with the process of IFN induction, independently of
ISG15, a possibility that remains to be explored.
A role for PKR in gene induction in response to HCV infection
has not been described before. Additional information was
therefore obtained through a transcriptome analysis of 2165 genes
in the Huh7.25.CD81 cells treated with control siRNAs or siRNAs
targeting PKR and infected with HCV for 12 hrs. Out of the most
significant 422 genes that were identified, 99 were unmodified or
barely modified and 33 were down-regulated, while 290 genes
were found to be up-regulated by HCV infection (data not shown).
Among those, HCV infection triggered up-regulation of 49 genes
which are directly dependent on PKR expression (Table 1). Forty
percent of these genes (20) belong to the family of the ISGs, with
ISG15 among the most induced genes (Table 1). In the reciprocal
situation, only 17 genes depended on PKR for their down-
regulation by HCV infection, with no link to a particular family of
genes and limited variation both in number and intensity (Table
S1). Thus, induction of ISGs upon HCV infection may occur
through a novel signaling pathway that involves PKR.
Induction of ISG15 by HCV is independent of RIG-I,
involves MAVS/TRAF3 association with PKR and involves
the DRBD region but not the catalytic activity of PKR
Infection with RNA viruses or transient transfection with
dsRNA can directly and rapidly induce early ISGs, such as ISG15,
through IRF3, after activation of the RIG-I/MAVS pathway and
recruitment of TRAF3, an essential adapter which recruits the
downstream IRF3 kinases TBK1/IKKe. We have shown that the
RIG-I pathway was not operative during HCV infection in the
Huh7.25.CD81 cells, precisely due to the presence of ISG15. To
determine how ISG15 induction through PKR relates to or differs
from the RIG-I/MAVS pathway, the Huh7.25.CD81 cells were
treated with siRNAs aimed at targeting separately PKR, RIG-I,
MAVS, TRAF3 and IRF3 (Figure S7) and infected with HCV.
The results clearly showed that induction of ISG15 in response to
HCV infection depends on PKR, MAVS, TRAF3 and IRF3 but
not on RIG-I (Figure 5A). The participation of IRF3 was further
confirmed by immunofluorescence studies which showed its
nuclear translocation at 6 hours post-infection (Figure S8).
ISG15, as well as ISG56, was also clearly induced in response to
HCV infection in two other HCV permissive cell lines, such as
Huh7 and Huh7.5 cells, and this induction was abrogated in
presence of siRNAs targeting PKR (Figure 5B and Figure S9).
Importantly, since Huh7.5 cells express a non-functional RIG-I/
MAVS pathway due to a mutation in RIG-I, result with these cells
supports the notion that the ability of HCV to trigger induction of
ISGs through PKR is independent of RIG-I. To have more
insights on this novel PKR signaling pathway, PKR was
immunoprecipitated at early times points following infection of
Huh7.25.CD81 cells with HCV and the immunocomplexes were
analysed for the presence of MAVS, TRAF3 and RIG-I. Both
MAVS and TRAF3, but not RIG-I, associate with PKR in a time
dependent manner, beginning at 2 hrs post-infection (Figure 5C).
Strikingly, these associations were abrogated by the cell-permeable
peptide PRI which is analogous to the first dsRNA binding
TRIM25 after IFN treatment was shown by immunoblot (C). (E) The Huh7.25.CD81 cells were transfected for 48 hrs with 5 mg of His-Myc-Ubiquitin
expression plasmid in absence or presence of a plasmid expressing HA-TRIM25 and infected with SeV (40 HAU/ml) or HCV (m.o.i=6). At the times
indicated, 10% of the lysate was precipitated with TCA and the remaining lysate subjected to nickel pulldown under denaturing conditions. Total and
ubiquitin (Ub)-modified proteins were separated by SDS-PAGE and revealed by immunoblot.
doi:10.1371/journal.ppat.1002289.g001
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PLoS Pathogens | www.plospathogens.org 4 October 2011 | Volume 7 | Issue 10 | e1002289Figure 2. HCV controls RIG-I ubiquitination through ISG15. (A) Huh7.25.CD81 cells were transfected for 24 hrs with 25 nM of siRNA (Control
or ISG15) and for another 24 hr with 5 mg of a His-Myc-Ubiquitin plasmid in absence or presence of 5 mg of a plasmid expressing HA-TRIM25. The cells
were infected with JFH1 (m.o.i=0.2). At the times indicated, cell extracts were processed for analysis of RIG-I ubiquitination and the expression of the
different proteins in the total cell extracts. (B) Huh7.25.CD81 cells were first transfected with siRNA Control (25 nM), si RNA ISG15 (25 nM), siRNA
Ube1L (50 nM) or left untreated. After 24 hrs, the untreated cells were transfected with a plasmid expressing HA-ISG15 (500 ng) alone or in presence
of plasmids expressing E1, E2 and E3 (1 mg each) while a set of cells transfected with siRNA Ube1L received plasmids expressing HA-ISG15, E2 and E3.
After 24 hrs, the cells were infected with JFH1 (m.o.i=6) for the times indicated. Stimulation of endogenous IFNb RNA expression was determined by
RTqPCR and expressed as fold induction. The degree of statistical significance is indicated by stars after calculation of the p-values (from left to right:
0.0005, 0.0076, 0.0003, 0.047 and 0.0023). (C–D) Huh7.25.CD81 cells, transfected with 25 nM of siRNA (Control or ISG15) for 48 hrs, were infected with
JFH1 (m.o.i=6) for the times indicated. Expression of IFNb or HCV RNA, determined by RTqPCR, was expressed as fold induction (C; IFNb) or as copies
(D; HCV). Error bars represent the mean 6S.D for triplicates. Expression levels of IFNb RNA at the start of infection were 2.1610
4 (siControl) and 4610
4
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compound which inhibits the catalytic activity of PKR
(Figure 5D). In line with this, PRI but not C16, abrogated the
ability of HCV to induce ISG15 (Figure 5E). The same result was
obtained for induction of ISG56 (Figure S10). We then used
human primary hepatocytes (HHP) to determine whether HCV
was also able to induce ISGs through PKR in a more physiological
cellular model. A follow-up of the infection over a period of
96 hours showed that JFH1 was replicating correctly in those cells
as well as leading to induction of ISG15 (10-fold) and to some
induction of IFNb (2.5-fold). These cells were infected with JFH1
for 8 hours in the absence or presence of PRI, making convenient
copies (siISG15). Supernatants collected at different times post-infection were used to infect fresh cells. After 24 hours, the RNAs were extracted from
the cells and expression of HCV RNA was determined by RTqPCR. (E) Huh7.25.CD81 cells, transfected with 25 nM of siRNA (Control or ISG15) for
48 hrs, were infected with JFH1 for the times indicated. Cell extracts were analysed by immunoblot with Abs directed against ISG15, MAVS, the HCV
NS3 and core proteins and Actin as loading control.
doi:10.1371/journal.ppat.1002289.g002
Figure 3. ISG15 strengthens the pro-HCV activity of PKR. (A–B). The Huh7.25.CD81 cells were transfected with 25 nM of the different siRNA
(Control, ISG15, PKR), separately or together. After 48 hrs, cells were infected with JFH1 (m.o.i=0.2). At the times indicated, expression of HCV or IFNb
RNA was determined by RTqPCR and expressed as copies of JFH1 RNA (A) or as fold induction (IFNb; B). The expression levels of IFNb RNA at the start
of infection was 6.96610
5 copies. (C) Two sets of Huh7.25.CD81 cells were first transfected with siRNA ISG15, siRNA PKR separately and together for
24 hrs, then transfected with the reporter plasmids IFNb-firefly luciferase (pGL2-IFNb), pRL-TK Renilla-luciferase for another 24 hrs and infected with
JFH1 (m.o.i=0.2) for the times indicated. In each case, IFN expression was expressed as fold-induction over control cells that were simply transfected
with pGL2-IFNb-FLUC/pRL-TK-RLUC. The graph represents the level of firefly luciferase activity normalized to the ratio R-luc RNA/GAPDH RNA. Such
normalization is required because of the negative control of general translation through PKR after 12 hrs post-infection [8]. Error bars represent the
mean 6S.D for triplicates. (D) Huh7.25.CD81 cells, in 100 cm
2 plates, were transfected with siRNA Control or siRNA ISG15 or transfected with a
plasmid expressing HA-ISG15 for 48 hrs and infected with JFH1 (m.o.i=6). At the indicated times post-infection, cell extracts (2.2 mg) were processed
for immunoprecipitation of PKR or for incubation with mouse IgG as a control of specificity (asterisk). The immunoprecipitated complexes were run
on two different NuPAGE gels and blotted using Mab 71/10 or anti-phosphorylated PKR antibodies (PKR-P). The presence of PKR and PKR-P was
revealed using the Odyssey procedure. The ratio PKR-P/PKR in the absence or in the presence of ISG15, either endogenous or endogenous and
ectopic, is shown in Figure S5.
doi:10.1371/journal.ppat.1002289.g003
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PLoS Pathogens | www.plospathogens.org 6 October 2011 | Volume 7 | Issue 10 | e1002289Figure 4. HCV triggers a PKR-dependent pathway early in infection to induce ISG15 and other genes. (A–C) The cDNAs reversed
transcribed from the RNAs extracted from the Huh7.25.CD81 cells for the experiment described under Figure 3A were analysed by qPCR for the
expression of ISG15 (A) and ISG56 (B). Expression levels of ISG15 and ISG56 RNA at the start of infection were respectively 1610
5 and 1.18610
5
copies. A novel set of Huh7.25.CD81 cells were transfected with siRNA Control, siRNA ISG15, siRNA PKR separately and together for 48 hrs. They were
then transfected with the reporter plasmids ISG56-FLUC and pRL-TK-RLUC and infected with JFH1 (m.o.i=0.2). At the times indicated, the effect of
the different conditions of silencing on the reporter expression was analyzed after normalization performed as described under Figure 3C (C). Results
are expressed as fold induction. Error bars represent the mean 6S.D for triplicates. (D) Huh7.25.CD81 cells were either transfected with 25 nM of
siRNA Control or siPKR for 24 hrs and infected with SeV for the times indicated. Expression of endogenous ISG15 was determined by RTqPCR and
expressed as fold induction. Error bars represent the mean 6S.D for triplicates. The expression levels of ISG15 RNA at the start of infection were
respectively 4.91610
4 copies (siControl) and 5.44610
4 copies (siPKR). (E) Huh7.25.CD81 cells were either transfected with 25 nM of siRNA Control or
HCV Controls IFN Induction through PKR and ISG15
PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002289use of the cell-penetrating ability of this peptide. Longer period of
treatment with PRI were not investigated for practical reasons (see
Materials and Methods). The results showed that PRI was
significantly inhibiting the induction of ISG15 while it had no
effect on that of IFNb (Figure 5F). Altogether, these data
demonstrate that HCV triggers induction of early ISGs through
MAVS and TRAF3 by using PKR as an adapter protein.
PKR interacts both with MAVS and TRAF3 and binds HCV
RNA ahead of RIG-I
The ability of HCV to control activation of the RIG-I/MAVS
pathway after induction of ISG15 through a novel PKR/MAVS
pathway suggests that PKR has the possibility to bind MAVS prior
to RIG-I. To determine this, we established the kinetics of these
interactions, after treating the Huh7.25.CD81 cells with siRNAs
targeting ISG15 prior to HCV infection. This was necessary in
view of the negative control of ISG15 on RIG-I. MAVS was
immunoprecipitated from the cell extracts at different times post-
infection and the presence of PKR and RIG-I was examined in the
immunocomplexes, as well as that of TRAF3, used as marker of
activation of the MAVS signaling pathway. As expected, only
PKR was able to associate with MAVS and TRAF3 in the control
cells (Figure 6A) whereas both PKR, RIG-I and TRAF3 were
found in the immunocomplexes in the absence of ISG15
(Figure 6B). The PKR/MAVS association took place at 4 hrs
post-infection in the control cells but was observed 2 hrs earlier in
the ISG15-depleted cells. Whether ISG15 plays a role in the
regulation of the PKR/MAVS association remains to be
determined. However, the presence of TRAF3 in association with
MAVS at 2 hrs post-infection in the control cells (Figure 6A)
correlates with its association with PKR (Figure 5C) which
indicates that the MAVS pathway can be activated through PKR
as soon as 2 hrs post infection. In ISG15 knock-down cells, the
RIG-I/MAVS association occurred later at 6 hrs post-infection
with an increase in TRAF3 association at 9–12 hrs post infection.
Altogether, these data revealed that HCV infection triggers an
earlier interaction of MAVS with PKR than with RIG-I.
Finally, we asked whether PKR was able to associate with HCV
RNA and how this association can be compared to that of RIG-I.
PKR and RIG-I were immunoprecipitated at 2, 4 and 6 hrs post-
infection and the presence of HCV RNA was analysed in the
complexes. The results showed that PKR associates with HCV
RNA with best efficiency at 2 hrs post-infection. Importantly, this
association was strongly inhibited in presence of PRI, thus
confirming the importance of PKR DRBD in the process. In
contrast, the association of HCV RNA with RIG-I was detected
only at 6 hrs post-infection. Interestingly, the association between
RIG-I and HCV RNA was not affected by PRI, which rules out
the possibility that the initial formation of a complex between
PKR and HCV RNA was a pre-requisite for the subsequent
binding of RIG-I to HCV RNA. Immunoprecipitation of PKR at
1, 2, 4 and 6 hrs post-infection, in presence of an inhibitor of
ribonucleases also did not lead to detection of RIG-I in the
complexes (Figure S11). Association of HCV RNA with eIF2a,
used as negative control, was not significant, thus showing the
specificity of the assay (Figure 6C). Whether a direct interaction
of PKR with HCV RNA represents the initial event leading to the
MAVS-dependent induction of early ISGs remains now to be
characterized. Altogether, these data reveal an earlier mobilization
of PKR than RIG-I in response to HCV infection which leads to
activation of a MAVS-dependent signaling pathway.
Discussion
Hepatitis C virus can attenuate IFN induction at multiple levels
in infected hepatocytes, such as through the NS3/4A-mediated
MAVS cleavage [7,27] and by using the eIF2a kinase PKR to
control IFN and ISG expression at the translational level [8,9].
Here, we have identified another process by which HCV controls
IFN induction at the level of RIG-I ubiquitination through ISG15
and an ISGylation process. Importantly, we have shown that
ISG15 is rapidly induced, among other ISGs, in response to HCV
infection, through a novel signaling pathway that involves PKR,
MAVS, TRAF3 and IRF3 but not RIG-I. In this pathway, PKR is
not used for its kinase function but rather as an adapter protein
with its dsRNA binding domain (DRBD) playing an essential role
in this mechanism (Figure 7). By transcriptome analysis, we
showed that HCV induces a number of ISGs in the HCV-
permissive Huh7.25.CD81 cells and we confirmed the induction of
two of these, ISG15 and ISG56, in other HCV-permissive cells,
such as Huh7.5 and Huh7 cells. In addition, induction of ISG15
by HCV in a PKR-dependent manner was confirmed in human
primary hepatocytes. The ability of HCV to trigger high
expression levels of ISG15 and ISG56, as well as other ISGs,
has previously been reported in models of HCV-infected chim-
panzees [10,12,28] and in HCV-infected patients [14,15,16].
Induction of ISGs thus represents a general propriety of the
response of the cells to HCV. In addition to this, natural variations
in intra-hepatic levels of ISG15 in vivo may increase the
susceptibility of some patients to HCV infection. The ability of
HCV to control RIG-I activity through ISG15 is important to
note in view of several reports which highlight the importance of a
role for ISG15 in the maintenance of HCV in livers [15,16] or in
the control of HCV replication in cell cultures [17,25]. Our data
provide an explanation for the presence of ISGs at high expression
levels in HCV-infected patients [14,15,16] and in models of HCV-
infected chimpanzees [10,12,28] in the absence of, or with poor
IFN expression.
The 15 Kda ISG15, or Interferon Stimulated Gene 15 [29],
also known as ubiquitin cross reactive protein (UCRP) [30], can be
conjugated (ISGylation) to more than 150 cellular protein targets
[31] through the coordinated action of three E1, E2 and E3-
conjugating enzymes, in a process similar but not identical to
ubiquitination. While both ubiquitin and ISG15 can use the same
E2 enzyme UbcH8, Ube1L functions as a specific E1 enzyme
for ISG15, in spite of its 45% identity with Ube1, the E1 enzyme
for ubiquitin [32]. The major E3 ligase for human ISG15 is
HERC5 [33].
Interestingly, RIG-I was identified as a target for ISG15, among
other IFN-induced proteins or proteins involved in IFN action
[31]. However, its activity appears to be negatively controlled by
ISG15 and the ISGylation process, either as shown previously
after cotransfection with the ISG15 and the ISG15-conjugating
enzymes [18] or as shown here, in a model of infection with HCV.
Indeed, ISG15 is now emerging as playing a proviral role in case
of HCV infection. Several reports now highlight the importance of
a role for ISG15 in the control of HCV replication in cell cultures
[17,25] as well as in the maintenance of HCV in livers and
siISG15 and with 1 mg of a plasmid expressing PKR where indicated. After 48 hrs, the cells were infected with HCV (m.o.i=6) for the times indicated.
Expression of HCV, ISG15 and IFNb RNA was determined by RTqPCR. Cell lysates prepared from cells treated in the same conditions but not infected
were used to control expression of PKR and ISG15 by immunoblot.
doi:10.1371/journal.ppat.1002289.g004
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SiPKR mock/siCt Name Access. N. siCtMock siCt HCV siCtMock’ siPKRHCV LOG2*
0,6 ISG56 NM_001548 15,0 885,8 10,2 7,6 -6,3
0,7 ISG15 NM_005101 593,6 26061,9 410,6 283,5 -6,0
0,7 IFI 9-27/IFITM1 NM_003641 27,8 817,7 15,1 10,1 -5,5
1,2 IFI1-8U NM_006435 24,0 597,7 10,9 7,2 -5,3
1,1 Olfactory Receptor 9l1 NM_001005211 26,6 473,1 10,1 4,8 -5,2
1,6 IFI1-8U XM_084845 17,7 365,4 9,3 6,5 -4,9
0,8 OASp100 NM_006187 46,4 909,9 40,0 33,5 -4,5
0,8 IFI6-16 NM_002038 834,5 10040,6 45,9 24,1 -4,5
0,6 Ub2L6 NM_004223 392,7 4078,9 281,2 128,7 -4,5
0,9 OAS 1 NM_016816 49,9 704,03 31,8 21,6 -4,4
0,9 ISG12 NM_005532 46,3 592,54 38,3 29,2 -4,1
0,8 IFP 35 NM_005533 36,3 369,7 26,6 16,9 -4,0
0,6 PARP-9 NM_031458 29,5 318,5 37,8 25,6 -4,0
0,5 GABA-B receptor 1 NM_006398 29,5 500,8 26,0 28,5 -4,0
0,7 Lysp100B NM_003113 8,7 93 8,5 6,1 -3,9
0,8 PDIP1 NM_033405 27,4 146,6 28,0 12,8 -3,6
0,8 PKR NM_002759 48,2 306,8 47,0 26,0 -3,5
1,6 MT-IM NM_176870 49,0 1371,8 6,9 19,6 -3,3
0,7 Phospholipid scramblase NM_021105 170 1137,2 189,9 153 -3,1
1,1 RIG-I NM_014314 23,5 223,2 18,9 21,9 -3,0
0,6 IFIT-5 NM_012420 24,9 95,3 35,0 21,3 -2,7
1,3 RIG-I NM_004585 7,4 42,5 6,3 6,0 -2,6
0,7 STAT1 beta NM_139266 336,9 1401,5 300,3 210,3 -2,6
0,8 BRCA1 C-ter assoc. Prot NM_001040444 12,3 45,1 8,1 5,1 -2,6
0,9 Cohesin Rec8 homolog NM_005132 18,0 103 16,7 16,9 -2,5
0,5 C/EBPdelta NM_005195 324,9 901,8 278,9 161,27 -2,3
0,7 ZNF532 NM_018181 32,8 146,5 25,5 23,8 -2,3
0,6 NNMT NM_006169 52,8 143,8 50,26 28,9 -2,2
1 ISG1-8U XM_084845 32,0 146,8 23,1 22,7 -2,2
1,1 HIF00 NM_153833 45,3 199,9 34,7 32,9 -2,2
0,8 ISG20 NM_002201 129,3 338,3 107,5 61,4 -2,2
1,1 PSMB10 NM_002801 16,2 75,1 14,5 15,0 -2,2
1,3 ZC3HAV1 NM_024625 8,3 26,0 6,9 4,9 -2,1
0,9 SOD2 NM_000636 348,5 1612,2 311 334,3 -2,1
0,7 PARP12 NM_022750 269,9 875,2 296,9 224,2 -2,1
0,7 NMI NM_004688 32,1 136 37,4 37,0 -2,1
0,8 NEDD9 NM_006403 5,7 19,0 5,7 4,7 -2,0
1,1 SAMHD1 NM_015474 17,1 49,5 13,6 9,7 -2,0
0,7 AKT2 NM_001626 13,4 20,0 14,2 5,4 -2,0
0,5 ARG1 NM_000045 245,9 282,6 231,4 67,0 -2,0
0,8 BHLHB2 NM_003670 76,4 128,0 71,5 30,5 -2,0
0,8 LGALS3BP NM_005567 22,0 72,0 16,1 13,6 -2,0
1,3 ZNF292 XM_048070 22,3 31,4 20,2 7,3 -2,0
1,1 STAT1 NM_007315 53,3 275,3 48,2 64,9 -1,9
0,7 TBA3_HUMAN NM_006009 28,2 43,6 33,4 13,7 -1,9
0,5 TM4SF20 NM_024795 45,2 51,0 36,9 11,1 -1,9
1,4 ERAP2 NM_022350 9,8 19,2 8,8 4,6 -1,9
0,8 USP18 XM_001126794.1 215,1 979,2 201,8 245,9 -1,9
1 USP18 XM_001126794.1 129,6 617,0 127,3 165,5 -1,9
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IFN therapy [14,15,16].
At present, we do not know at which level ISGylation regulates
IFN induction in response to HCV infection. An HCV-mediated
increase of ISG15 would favour preferential binding of ISG15
over that of ubiquitin to the E2 enzyme UbcH8 and hence
enhance the spatio-temporal availability of UbcH8-ISG15 for
HERC5 over that of UbcH8-ubiquitin for TRIM25. It may also
lead to inhibition of TRIM25, through autoISGylation [21,34],
which would decrease its ability to ubiquitinate RIG-I. We showed
that overexpression of HERC5 together with Ube1L, UbcH8 and
ISG15 was increasing the ability of ISG15 to inhibit IFN induction
by HCV (Figure 2B). All three enzymes Ube1L, UbcH8 and
HERC5 belong to the family of genes induced by IFN and it has
been reported that ISGylation is optimum in a context of IFN
treatment [18,35]. Therefore, it is tempting to speculate that
elevated levels of ISG15 in some HCV-infected patients would
bring the most favourable context for the virus when those patients
are under IFN therapy. This would be in accord with the clinical
data showing that HCV-induced high expression of ISG act as a
negative predictive marker for response to IFN therapy.
It is doubtful that viruses with high IFN-inducing efficiency,
such as Sendai virus may control RIG-I through ISG15 and PKR.
However, viruses that avoid inducing IFN may have use of the
PKR pathway. A good example might be that of Hepatitis B Virus
(HBV) [36,37,38]. PKR expression was previously reported to be
elevated in HCC liver from chronically HBV infected patients [39]
and a relationship between PKR and IFN induction during HBV
infection would be important to evaluate.
At present, we have established that HCV RNA interacts with
PKR as soon as 2 hours post-infection. This interaction occurs
prior the interaction of HCV RNA with RIG-I, which suggests
that PKR may rapidly detect structures containing the incoming
HCV RNA genome. Indeed, PKR has been reported to bind the
dsRNA domains III and IV of HCV IRES [40] in addition to its
ability to also bind 59 triphosphorylated ss or dsRNA structures
[41]. Whether PKR behaves as a pathogen recognition receptor
for HCV RNA, like RIG-I, remains to be clarified. It is however
clear that, in contrast to RIG-I, PKR acts here in favour of the
pathogen rather than in favour of the host defense. We have
established that the HCV RNA/PKR interaction depends on the
first DRBD present at the N terminus of PKR and is independent
on its kinase activity. The ability of PKR to serve as adapter in
signaling pathways is not a total surprise since it has been
previously shown to activate NF-kB through interaction of its C
terminus with members of the TRAF family, such as TRAF5 and
TRAF6 [42]. PKR contains also TRAF interacting motif in its N
terminus [42] and an association between TRAF3 and PKR has
been reported upon cotransfection in 293T cells [43]. Intriguingly,
PKR was previously reported to participate in the induction of
IFNb, in association with MAVS, through activation of NF-kBo r
ATF-2 but not or partially IRF3; however these studies were not
performed in the absence of RIG-I [44,45,46]. The mode of
interaction between PKR, TRAF3 and MAVS, independently of
RIG-I, and how it leads to a preferential induction of ISGs and not
of IFNb in response to HCV infection in contrast with the RIG-I/
MAVS pathway remains to be determined. Based on our data, we
propose now to divide the innate response to acute HCV infection
into two phases: an early acute phase in which PKR is activated
and a late acute phase that depends on RIG-I, the early phase
controlling activation of the late phase. It is now essential to
progress towards the generation of specific pharmaceutical
inhibitors targeting PKR in order to abrogate the early acute
phase to the benefit of the RIG-I-driven late phase. In a more
general view, care should now be taken in the choice of
compounds designed to be used as immune adjuvants, such as
to be devoid of activation of the early acute PKR phase. This will
ensure their efficiency as to activate properly the innate immune
response through the late acute RIG-I phase.
Methods
Cell cultures and viruses
The culture of Huh7, Huh7.5, Huh7.25.CD81 cells, the
preparation of Sendai virus stocks (<2000 HAU/ml) and of
HCV JFH1 stocks (<6.10
4 FFU/mL and <6.10
6 FFU/mL) was
as described [8,47]. Preparation and cultures of human primary
hepatocytes was as described [48]. Of note, the ability of the
Huh7.25.CD81 cells to induce IFN in response to SeV without
prior IFN treatment (40-fold) was not observed in our previous
study [8].The ability of Sendai virus to induce IFN is related to the
presence of copyback DI (Defective Interfering) genomes [49].
The higher IFN inducing ability of the novel Sendai virus stock
may have come from an important accumulation of these
copyback DI genomes, during its growth in chicken eggs.
PKR inhibitors
The C16 compound [50] and the cell-permeable PRI peptide
[51] were provided by Jacques Hugon. These drugs were applied
(200 nM for C16 and 30 mM for PRI) one hour before the end of
the 2 hr- incubation time with JFH1 and re-added to the medium
after washing the cells with phosphate buffered saline (PBS). Note
that PRI loses its effect very rapidly, probably through degradation
in the cells, and requires to be added every hour to the cells until
the end of treatment.
Expression vectors
TRIM25 was cloned from the IFN-treated Huh7.25CD81 cells
(500 U/ml IFN-a2a; Cellsciences) after RT-PCR using the
forward: 59-ATGGCAGAGCTGTGCCCCCT-39 and reverse 59-
CTACTTGGGGGAGCAGATGG-39 primers. The pcDNA3.1(+)
vector expressing 59HA tagged-TRIM25 (provided by D. Garcin;
University of Geneva, Switzerland) was used to generate the
TRIM25 P358L construct by site-directed mutagenesis. The
The Huh7.25.CD81 cells, seeded at 3.10
6 cells in 10-cm plates, were transfected after 24 hrs with 25 nM of siRNA Control or siRNA PKR using Fugene HD. 24 hrs post
transfection, they were either mock-infected or infected for 2 hrs at 37uC with JFH1 (moi=0.2) (three independent plates/sample). The medium was then removed and
cells were incubated with complete DMEM for 12 hrs at 37uC. The cells were washed twice with TBS containing phosphatase and protease inhibitors, harvested by
scraping, the cell pellets were centrifuged, the supernatants were removed and the pellets were frozen and stored at 280uC before being processed for micro-array.The
list shows genes that were affected no more than twice by the depletion of PKR in the control cells (0.5, siPKR mock/siCt ,1.6). The dependence of each of these
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PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002289Figure 5. HCV-dependent induction of ISG15 involves PKR, MAVS and TRAF3 and not RIG-I. (A–B). A-The Huh7.25.CD81 cells were
transfected with 50 nM Control siRNA and the different Smartpool siRNAs (50 nM siPKR; 10 nM siRIG-I; 5 nM siMAVS; 50 nM siTRAF3; 50 nM siIRF3)
for 48 hrs and infected with JFH1 (m.o.i=6). (B) Huh7.5 or Huh7 cells were transfected with siRNA Control or siPKR (50 nM) for 48 hrs and infected
with JFH1 (m.o.i=0.2 for Huh7.5 or 10 for Huh7). At the times indicated, expression of endogenous ISG15 was determined by RTqPCR and expressed
as fold induction. Error bars represent the mean 6S.D for triplicates. The expression level of ISG15 RNA at the start of infection in the siControl cells
was 9.97610
4 copies (Huh7.25.CD81), 1.31610
4 copies (Huh7.5) and 1.28610
4 (Huh7). (C–D) Huh7.25.CD81 cells, in 100 cm
2 plates, were infected
with JFH1 (m.o.i=0.2) alone (C) or in presence of PRI or C16 (D). At the times indicated, cell extracts (3.5 mg) were processed for
immunoprecipitation of PKR or for incubation with mouse IgG as a control of specificity (asterisk). The detection of the proteins in the complexes and
in the whole cell extracts (WCE) was revealed by immunoblot using the Odyssey procedure. (E) The Huh7.25.CD81 cells were incubated with PRI or
C16 and infected with JFH1 (m.o.i=0.2) for the times indicated. Expression of endogenous ISG15 was determined as in A–B. The ISG15 RNA levels
were 3.81610
4 copies in the siControl cells. (F) Human primary hepatocytes (HHP) were infected with JFH1 (m.o.i=6). One set of cells was incubated
with 30 mM of the PRI inhibitor during 8 hours. At the times indicated, expression of HCV RNA, ISG15 and IFNb was determined by RTqPCR. The
expression levels of ISG15 and IFNb RNA at the start of infection was 1.05610
5 copies and 1,11610
4 copies, respectively. Inhibition of induction of
ISG15 by PRI at 8 hr post-infection was statistically significant (***; p=0.0001).
doi:10.1371/journal.ppat.1002289.g005
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PLoS Pathogens | www.plospathogens.org 11 October 2011 | Volume 7 | Issue 10 | e1002289Figure 6. PKR both interacts with MAVS and TRAF3 and binds HCV RNA ahead of RIG-I. (A–B)- Huh7.25.CD81 cells were transfected with
25 nM of siRNA Control (A) or 25 nM of siRNA ISG15 (B) for 48 hrs and infected with JFH1 (m.o.i=0.2). At the times indicated, cell extracts (4.5 mg)
were incubated with anti-MAVS antibodies. In addition, cell extracts prepared at 0 hr post-infection were incubated with mouse IgG as a control of
specificity (asterisk). The immunoprecipitated complexes were run on three different NuPAGE gels and blotted using Mab 71/10, anti-MAVS, anti-RIG-I
or anti-TRAF3 antibodies. The expression level of each protein was controlled in the total cell extracts. (C)- Huh7.25.CD81 cells were incubated with
JFH1 (m.o.i=6) for 2 hrs at 37uCo ra t4 uC in the absence or presence of 30 mM of PRI. This drug was applied one hour before the end of the
incubation time. After washing the cells twice with PBS, the cells were further incubated for 2, 4 or 6 hrs at 37uCo ra t4 uC in the absence or presence
of PRI (added every hour). The cell extracts were processed for crosslinking of RNA to proteins before lysis, as described in Materials and Methods and
different immunoprecipitations were performed with antibodies directed against PKR, RIG-I or eIF2a. After extensive washing, the presence of HCV
RNA linked to the immunocomplexes was analysed by RTqPCR and the presence of the proteins was verified by Western blot. Measure of HCV RNA in
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luciferase reporter plasmids were described previously [8]. The
pGL3 luciferase reporter construct containing the 23t o2654
nucleotides of the ISG56 promoter was provided by N.Grandvaux
[52]. The Myc-HIS-Ubiquitin construct was provided by R.Kopito
(Stanford University, CA). ISG15 was cloned from IFN-treated
Huh7 cells using the forward: 59- GGATCCCATGGGCT-
GGGACCTGACGGTG-39 and reverse 59-CTCGAGCTCC-
GCCCGCCAGGCTCTGT-39 primers and inserted into the
pcDNA3.1(+)HA vector. The Ube1L, UbcH8 and HERC5
constructs were kindly provided by Jon M. Huibregtse [35]. The
pcDNA1/AMP vector expressing PKR has been described previ-
ously [53].
RNA-mediated interference
The siRNAs directed against PKR, MAVS, RIG-I, TRAF3 and
IRF3 which were used for the experiment described in figure 5A
correspond to pools of siRNA (Smartpool) obtained from
Dharmacon Research, Inc. (Lafayette, CO), as well as siRNAs
directed against Ube1L used in Figure 2B. Control (scrambled)
siRNA and siRNA directed against PKR or ISG15, used in all
other experiments, were chemically synthesized by Dharmacon
the cell extracts allowed to estimate its percentage of binding to PKR as 1.09%, 0.47% and 0.25% at 2, 4 and 6 hrs post-infection respectively, and its
percentage of binding to RIG-I as 0.34% at 6 hrs post-infection.
doi:10.1371/journal.ppat.1002289.g006
Figure 7. Multiple levels of control of IFN induction during HCV infection. Soon after infection, the HCV RNA is detected by the dsRNA
binding domains (DRBD) of PKR ahead (2 hr) of its recognition by the RNA helicase RIG-I (6 hr). Recruitment of PKR by HCV triggers a signaling
pathway that involves PKR as an adapter protein to recruit MAVS and TRAF3. This leads to a strong induction of the di-ubiquitine like protein ISG15 as
well as other IRF3-dependent ISGs (Interferon-Stimulated Genes). ISG15 negatively controls the TRIM25-mediated ubiquitination (Ub) of RIG-I through
an ISGylation process and thus interferes with the ability of RIG-I to recruit its downstream partners, including MAVS and TRAF3, and to induce IFNb
and ISGs. As the infection proceeds, HCV activates the eIF2a kinase function of PKR (12 hr). This leads to a transient (few hours) inhibition of general
translation, including that of IFN [8] and ISGs [9] while the eIF2a-independent translation of the viral proteins proceeds unabated. At later times in the
infection (18 hr), additional control of IFN induction occurs through cleavage of MAVS by the HCV NS3/4A protease, once the viral proteins have
sufficiently accumulated in the cytosol [7,27].
doi:10.1371/journal.ppat.1002289.g007
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(Text S1). The siRNAs (final concentration 25 nM or 50 nM)
were transfected for 48 h using jetPRIME reagent according to
the manufacturer’s instructions (PolyPlus transfection TM) before
transfection with other plasmids or before infection.
Antibodies
Mab to ISG15 (clone 2.1) was a kind gift of E.Borden [54]. Mab
to PKR was produced from the murine 71/10 hybridoma (Agro-
bio; Fr) with kind permission of A.G.Hovanessian [55]. Other
antibodies were as follows: anti-mouse IgG (Santa Cruz), anti-
TRAF3 (Santa Cruz), pThr451-PKR (Alexis), MAVS (Alexis),
anti-actin (Sigma), anti-pSer10-Histone H3 (Millipore), anti-HCV
NS3 (Chemicon), anti-HCV core (Thermo scientific), anti-RIG-I
(Alexis Biochemical Inc.), anti-TRIM25 (6105710; BD Biosci-
ence), anti-IRF3 (Santa Cruz), anti-HA (12CA5; Roche) and anti-
Myc (Santa Cruz).
Reporter assays
Huh7.25.CD81 cells (80,000 cells/well; 24-well plates) were
transfected with 40 ng of pRL-TK Renilla-luciferase reporter
(Promega) and 150 ng of either pGL2-IFNb-Firefly luciferase
reporter or pISG56-luciferase reporter and processed for dual-
luciferase reporter assay as reported previously [8].
Real-time RT-PCR analysis
Total cellular RNA was extracted using the TRIZOL reagent
(Invitrogen). HCV RNA was quantified by one-step RTqPCR.
Reverse-transcription, amplification and real-time detection of
PCR products were performed with 5 ml total RNA samples, using
the SuperScript III Platinum one-step RTqPCR kit (Invitrogen)
and an AbiPrism 7700 machine. For the sequence of the different
primers, see Text S1. The results were normalized to the amount
of cellular endogenous GAPDH RNA using the GAPDH control
kit from EuroGentec. Copies number of HCV RNA may vary due
to internal calibration and depending on the preparation of the
viral stocks. All m.o.i were calculated using the titers expressed in
FFU/ml. The IFNb, ISG15, ISG56, Ube1L and GAPDH
amplicons were quantified by a two-step RTqPCR assay as
described [8].
Transcriptome analysis
Cellular RNA was extracted and purified from the cells using
RNAeasy mini kit (QIAGEN K.K., Tokyo, Japan). Comprehen-
sive DNA microarray analysis was performed with 3D-Gene
Human Oligo chip25k with 2-color fluorescence method by New
Frontiers Research Laboratories, Toray Industries Inc, Kama-
kura, Japan as previously described [56]. In brief, each sample was
hybridized with 3D-Gene chip. Hybridization signals were
scanned using Scan Array Express (PerkinElmer, Waltham,
MA). The scanned image was analyzed using GenePix Pro
(MDS Analytical Technologies, Sunnyvale, CA). All the analyzed
data were scaled by global normalization.
Immunoprecipitation and immunoblot analysis
Cells were washed once with PBS and scraped into lysis buffer 1
(50 mM TRIS-HCl [pH 7.5], 140 mM NaCl, 5% glycerol, 1%
CHAPS) that contained phosphatase and protease inhibitors
(Complete, Roche Applied Science). The protein concentration
was determined by the Bradford method. For immunoprecipita-
tion, lysates were incubated at 4uC overnight with the primary
antibodies as indicated and then in the presence of A/G-agarose
beads (Santa Cruz Biotechnology) for 60 minutes. The beads were
washed three times, and the precipitated proteins were extracted
at 70uC using NuPAGE LDS sample buffer. Protein electropho-
resis was performed on NuPAGE 4–12% Bis TRIS gels
(Invitrogen). Proteins were transferred onto nitrocellulose mem-
branes (Biorad), and probed with specific antibodies. Fluorescent
immunoblot images were acquired and quantified by using an
Odyssey scanner and the Odyssey 3.1 software (Li-Cor Bioscienc-
es) as described previously [8]. For detection of ISG15, cells were
lysed in RIPA buffer (50 mM TRIS-HCl [pH 8.0]; 200 mM
NaCl; 1% NP-40; 0.5% Sodium Deoxycholate; 0.05% SDS;
2 mM EDTA) and protein electrophoresis was performed on
4–20% polyacrylamide gels (PIERCE).
Nuclear/cytoplasmic extract
Pellets from cells washed in ice-cold phosphate-buffered saline
(PBS) were lysed in ice-cold cytoplasmic buffer (10 mM TRIS
[pH 8.0], 5 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100)
containing phosphatase and protease inhibitors. The suspension
was centrifuged for 30 seconds at 14,000 g and the supernatant
(cytoplasmic fraction) was transferred into microcentrifuge tubes.
The nuclear pellet was resuspended in Urea buffer (8 M Urea,
10 mM TRIS [pH 7,4], 1 mM EDTA, 1 mM dithiothreitol)
containing phosphatase and protease inhibitors, homogenized by
vortex and boiled for 10 minutes. The protein concentration was
determined by the Bradford method.
Ubiquitination assay
Huh7.25.CD81 cells were transfected for 48 hrs with 5 mgo f
Myc-His-Ubiquitin expression plasmid using jetPRIME reagent.
The cells were then washed in ice-cold PBS containing 20 mM
N-ethylmaleimide (Sigma-Aldrich), harvested directly in Gua8
buffer (6 M guanidine-HCl, 300 mM NaCl, 50 mM Na2HPO4,
50 mM NaH2PO4 [pH 8.0]), briefly sonicated, and centrifuged at
14,000 g for 15 min at 4uC. 1/10th of the lysate was subjected to
precipitation with 10% trichloroacetic acid for protein analysis in
whole cell extracts. The rest of the lysate was incubated for 2 hrs
with 20 ml (packed volume) of Talon resin Ni-affinity beads
(Clontech) on a rotating wheel. Bound proteins were washed four
times in Gua8 buffer, three times in Urea 6.3 buffer (8 M Urea,
10 mM TRIS, 0.1 M Na2HPO4, 20 mM Imidazole [pH 6.3]),
and three times in cold PBS, after which they were eluted by
boiling in NuPAGE LDS sample buffer. Electrophoresis was
performed on 4–12% of acrylamide NuPAGE gels (Invitrogen).
Co-precipitation protein/HCV RNA
Huh7.25.CD81 cells were incubated for 10 min in their culture
medium containing 1/10 volume (Vol) of a crosslinking solution
(11% Formaldehyde, 0.1 M NaCl, 1 mM Na-EDTA-[pH 8],
0.5 mM Na-EGTA-[pH 8], 50 mM HEPES [pH 8]). The
reaction was stopped by addition of a solution of 0.125 M glycine
in PBS [pH 8] at room temperature (RT). The cells were washed
three times in ice-cold PBS containing 1000 U/ml of RNAse
inhibitor (Promega), scraped in PBS and dispatched into three sets
containing K (set 1), J (set 2) and J (set 3) of the cell suspension.
The three sets were centrifuged for 30 seconds at 14,000 g and
4uC and the cell pellets were lysed into lysis buffer 1 containing
phosphatase/protease and RNAse inhibitors (Promega) for sets 1
and 2 or into TRIZOL reagent for set 3. Cell lysates from sets 1
and 2 were then incubated at 4uC, first overnight with the
appropriate primary antibodies and for 60 minutes in the presence
of A/G-agarose beads (Santa Cruz Biotechnology). After the
incubation period, the beads were washed four times with buffer 1.
Set 1 (HCV RNA bound to immunocomplexes) and set 3 (input
HCV RNA) were submitted to TRIZOL treatment and HCV
HCV Controls IFN Induction through PKR and ISG15
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previously. The immunoprecipitated proteins from set 2 were
extracted at 70uC using NuPAGE LDS sample buffer and
analysed by immunoblot after electrophoresis on 4–12% of
acrylamide NuPAGE gels (Invitrogen).
Supporting Information
Figure S1 Efficient induction of TRIM25 by IFN in the
Huh7.25.CD81 cells. Huh7.25.CD81 cells, seeded at 8610
4
cells in 24-well plates containing coverslips, were treated with
500 U/ml of IFNa for 24 hrs (IFN) or left untreated (Cont). Cells
were fixed with 4% PFA and TRIM25 was detected using anti-
TRIM25 antibodies (red). Nuclei are shown in blue after DAPI
labelling. Microscope magnification was 663.
(PDF)
Figure S2 HCV controls RIG-I ubiquitination through
ISG15 in the Huh7 cells. Huh7 cells were transfected for 24 hrs
with 25 nM of siRNA (Control or ISG15) and for another 24 hr
with 5 mg of a His-Myc-Ubiquitin plasmid in absence or presence
of 5 mg of a plasmid expressing HA-TRIM25. The cells were
infected with JFH1 (m.o.i=0.2). At the times indicated, cell
extracts were processed for analysis of RIG-I ubiquitination and
the expression of the different proteins in the total cell extracts.
Efficiency of infection by JFH1 in the Huh7 cells was 2 log less
than in the Huh7.25.CD81 cells.
(PDF)
Figure S3 Expression of ISG15 and ISG15 conjugating
enzymes inhibit IFN induction in response to SeV.
Huh7.25.CD81 cells were transfected with a plasmid expressing
HA-ISG15 alone or in the presence of plasmids expressing the
ISG15 conjugating enzymes Ube1L (E1), UbcH8 (E2) and
HERC5 (E3). The cells were then infected with JFH1 (m.o.i=6)
for the times indicated. Stimulation of endogenous IFNb RNA
expression was determined by RTqPCR and expressed as fold
induction. The degree of statistical significance is indicated by stars
after calculation of the p-values (from left to right: 0.0124 and
0.0058).
(PDF)
Figure S4 Control of efficiency of siRNA Ube1L in the
Huh7.25.CD81 cells. The Huh7.25.CD81 cells were transfect-
ed with 50 nM of siRNA directed against Ube1L for 48 hours and
infected with HCV. RNA was prepared from the cells at different
times post infection as indicated and expression levels of Ube1L
was determined by RTqPCR.
(PDF)
Figure S5 Modulation of PKR activation by ISG15.
Huh7.25.CD81 cells, in 100 cm
2 plates, were transfected with
siRNA Control or siRNA ISG15 or transfected with a plasmid
expressing HA-ISG15 for 48 hrs and infected with JFH1
(m.o.i=6). At the indicated times post-infection, cell extracts
(2.2 mg) were processed for immunoprecipitation of PKR. The
immunoprecipitated complexes were run on two different
NuPAGE gels and blotted using Mab 71/10 or anti-phosphory-
lated PKR antibodies (PKR-P). The presence of PKR and PKR-P
was revealed using the Odyssey procedure. The bands corre-
sponding to total PKR and phosphorylated PKR were quantified
using the Odyssey software and expressed as the ratio PKR-P/
PKR in the absence (siISG15) and in the presence of ISG15 in the
control cells (Control) or after transfection of the ISG15 expressing
plasmid (HA-ISG15).
(PDF)
Figure S6 Induction of ISG56 by Sendai virus in the
Huh7.25.CD81 cells does not depend on PKR.
Huh7.25.CD81 cells were either transfected with 25 nM of
siRNA Control or 25 nM siPKR for 24 hrs and infected with
SeV for the times indicated. The effect of PKR silencing on the
stimulation of expression of endogenous ISG56 was determined by
RTqPCR and expressed as fold induction. Error bars represent
the mean 6S.D for triplicates. The expression levels of ISG56





Figure S7 Control of the efficiency of siRNA treatment
in the Huh7.25.CD81 cells. The Huh7.25.CD81 cells were
transfected for 48 hrs with 50 nM Control siRNA or with the
different Smartpool siRNAs as shown (50 nM siPKR; 10 nM
siRIG-I; 50 nM siIRF3; 50 nM siTRAF3; 5 nM siMAVS). Total
cell extracts were prepared and the expression level of each
protein, as well as that of actin used as control, was revealed by
immunoblot and Odyssey procedure after a run on NuPAGE gels.
Under each lane, the numbers represent the quantification of the
different protein bands performed using the Odyssey software.
(TIF)
Figure S8 HCV triggers nuclear translocation of IRF3
early after infection in the Huh7.25.CD81 cells.
Huh7.25.CD81 cells, seeded at 10
5 cells in 24-well plates
containing coverslips, were infected for different times (0, 4 and
6 hours) at 37uC with JFH1 (moi=6) or with SeV (40 HAU/ml) in
the absence or in the presence of 10 ng/ml Leptomycine B (LB;
Sigma), which was used here as a convenient mean to enhance the
nuclear detection of IRF3 since it can interfere with nuclear export
[57]. Cells were fixed with 4% PFA and IRF3 was detected using
anti-IRF3 antibodies (red). Nuclei are shown in blue after DAPI
labelling. The arrows show the presence of IRF3 in the nucleus.
Microscope magnification was 663.
(PDF)
Figure S9 Induction of ISG56 by HCV in the Huh7.5 and
Huh7 cells depends on PKR. Huh7.5 or Huh7 cells were
transfected with siRNA Control or siPKR (50 nM) for 48 hrs and
infected with JFH1 (m.o.i=0.2 for Huh7.5 or 10 for Huh7). At the
times indicated, expression of endogenous ISG56 was determined
by RTqPCR and expressed as fold induction. Error bars represent
the mean 6S.D for triplicates. The expression levels of ISG56
RNA at the start of infection in the siControl cells was 1.37610
4
copies (Huh7.5 cells) and 1.28610
4 copies (Huh7 cells).
(PDF)
Figure S10 Induction of ISG56 by HCV is specifically
inhibed by the PKR inhibitor PRI. The Huh7.25.CD81 cells
were incubated with PRI or C16 and infected with JFH1
(m.o.i=0.2) for the times indicated. RTqPCR analysis of
endogenous ISG56 was determined by RTqPCR and expressed
as fold induction. The expression levels of ISG56 RNA at the start
of infection in the control cells was 1.97610
4 copies.
(TIF)
Figure S11 The RNAse inhibitor RNAsin does not favour
the formation of a RIG-I/PKR complex upon HCV
infection. Two sets of Huh7.25.CD81 cells were plated into
100 cm
2 plates and infected with JFH1. At the times indicated, cell
extracts (3.5 mg) from the two sets were processed similarly for
immunoprecipitation of PKR or for incubation with mouse IgG as
a control of specificity (asterisk), except that care was taken to add
the RNAse inhibitor RNAsin (1000 U/ml) at all steps for the
second set (+RNAsin). Detection of RIG-I, MAVS, and PKR in
HCV Controls IFN Induction through PKR and ISG15
PLoS Pathogens | www.plospathogens.org 15 October 2011 | Volume 7 | Issue 10 | e1002289the complexes and in the whole cell extracts (WCE) was revealed
by immunoblot using the Odyssey procedure. Detection of Actin
in WCE served as loading control.
(PDF)
Table S1 Transcriptome analysis of PKR-dependent
downpregulated gene upon 12 hrs of HCV infection.
Preparation of samples was as described under Table 1. The list
shows genes that were affected no more than twice by the
depletion of PKR in the control cells (0.5, siPKR mock/siCt
,1.6). The dependence of each of these genes in regards with
PKR for their inhibition by HCV is expressed as log2 (ratio
(siPKR HCV/siCt Mock)2(siCt HCV/siCt Mock) (indicated by
log2*) with a cut-off of <2.0 fold.
(DOC)
Text S1 Supplementary methods.
(DOC)
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